Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:11:19 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Q:NTRA - NATERA INC - https://www.natera.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NTRA - Q0.1203.05·246.502.5203.04+5.963.01,564.0312,08921,246199.73  203.68  194.02256.268  125.3818:42:5706:0015 min RT 2¢

Recent Trades - Last 10 of 21246
Time ETExPriceChangeVolume
18:42:57Q202.615.533
18:07:05Q205.007.921
17:43:06Q203.045.9617,389
17:24:44Q203.756.6774
17:16:34Q202.004.92100
17:00:46Q201.254.176
16:48:52Q202.375.293
16:43:48Q203.045.968,809
16:37:08Q203.045.961,346
16:17:19Q203.045.96222

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-06 06:00U:NTRANews ReleaseNatera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes
2026-02-02 06:00U:NTRANews ReleaseNatera Submits Signatera(TM) CDx PMA to FDA
2026-01-28 08:00U:NTRANews ReleaseNatera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
2026-01-26 06:00U:NTRANews ReleaseProspera(TM) Featured in Landmark Interventional Study Advancing Lung Transplant Care
2026-01-21 06:00U:NTRANews ReleaseNatera Publishes Clinical Validation of Latitude(TM) Tissue-Free MRD Test in Colorectal Cancer
2026-01-20 06:00U:NTRANews ReleaseNatera's Fetal Focus(TM) Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting
2026-01-13 08:00U:NTRANews ReleaseNatera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
2026-01-12 10:00U:NTRANews ReleaseNatera to Scale AI Foundation Models in Precision Medicine with NVIDIA
2026-01-11 22:48U:NTRANews ReleaseNatera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera(TM) Growth
2026-01-07 08:00U:NTRANews ReleaseExelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
2026-01-05 19:25U:NTRANews ReleaseNatera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
2026-01-05 07:00U:NTRANews ReleaseNatera Launches 21-Gene Fetal Focus(TM) Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP(TM) Technology
2025-12-22 08:00U:NTRANews ReleaseNatera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
2025-12-18 08:00U:NTRANews ReleaseNatera Announces Publication of Signatera(TM) Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
2025-12-16 08:00U:NTRANews ReleaseI-SPY 2 Publication in Nature Communications Shows Signatera(TM) Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
2025-12-12 08:00U:NTRANews ReleaseNatera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
2025-12-10 19:57U:NTRANews ReleasePhase III PALLAS Study Shows Signatera(TM) MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer
2025-12-09 08:00U:NTRANews ReleaseNatera Highlights New Findings in Lymphoma at the ASH Annual Meeting
2025-12-05 07:00U:NTRANews ReleaseNatera Acquires Foresight Diagnostics
2025-12-03 08:00U:NTRANews ReleaseNew Signatera(TM) Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting